- In March 2024, Orlucent received breakthrough device designation (BDD) from the US FDA for its skin fluorescence imaging system. This handheld, point-of-care device provides molecular-level imaging and analysis of moles, aiming to improve early detection and diagnosis of skin cancer. This advancement highlights the increasing focus on non-invasive, high-precision diagnostic tools in dermatology
- In February 2024, Iovance Biotherapeutics announced FDA accelerated approval for lifileucel (Amtagvi), an intravenous suspension for adult patients with unresectable or metastatic melanoma who have been previously treated. This represents a significant advancement in immunotherapy for advanced melanoma, offering a new treatment option for a challenging stage of the disease
